Mashup Score:39
JAMA NetworkSurvival in Patients With Hematologic Cancers and COVID-19 - 1 week
Mashup Score:39
Mashup Score:39
JAMA NetworkSurvival in Patients With Hematologic Cancers and COVID-19 - 1 week
Mashup Score:39
Mashup Score:9
New England Journal of Medicine (NEJM)Early Outpatient Treatment for Covid-19 with Convalescent Plasma | NEJM - 1 week
Mashup Score:9
Original Article from The New England Journal of Medicine — Early Outpatient Treatment for Covid-19 with Convalescent...
Early Outpatient Treatment for Covid-19 with Convalescent Plasma [Mar 30, 2022] @jhDavidSullivan et al. @NEJM https://t.co/Cqht9Cis3c #NCT04373460 #COVID19CP #COVID19 cc @DrMJoyner @DrJPHenderson @DFarmakiotis @covid19nCCC https://t.co/Cqht9Cis3c - view on twitter
Mashup Score:1
www.medrxiv.org| medRxiv - 1 day
Mashup Score:1
medRxiv – The Preprint Server for Health...
Characteristics of Patients with Hematologic Malignancies Without Seroconversion Post-COVID19 Third Vaccine Dosing {preprint} [Apr 16, 2022] Hallmeyer et al. @medrxivpreprint https://t.co/RZhhxFwJbu #COVID19Vaccine #COVID19nCancer #bmtsm #leusm #lymsm #mmsm #mpnsm #IDonc https://t.co/RZhhxFwJbu - view on twitter
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and...
Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc https://t.co/g3GP7EsUeS - view on twitter
PURPOSE Despite reported widespread use of dietary supplements during cancer treatment, few empirical data with regard to their safety or efficacy exist. Because of...
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients with Breast Cancer Enrolled in a Cooperative Group Clinical Trial (@SWOG S0221) [Dec 19, 2019] Ambrosone @cambros1 et al. @JCO_ASCO https://t.co/ZNBT5fdRRv #scicomm #oncopharm #bcsm - view on twitter
CCC19 is a consortium of 120+ organizations that are working together to collect data about patients with cancer who have been diagnosed with...
RT @COVID19nCCC: Map of Participating Institutions (N=126) - COVID-19 and Cancer Consortium (#CCC19) [Apr 20, 2022] https://t.co/xqZPC8wTjd… - view on twitter
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk...
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma [Mar 8, 2022] @AjayNookaMD et al. @JCO_ASCO https://t.co/nFlGvojgGz #mmsm #COVDID19nCancer #COVID19Vaccine #COVID19 #IDonc @WinshipAtEmory - view on twitter
COVID-19 in patients with hematological diseases is associated with a high mortality. Moreover, preventive vaccination demonstrated reduced efficacy and the knowledge on influencing factors...
Definition of factors associated with negative antibody response after COVID-19 vaccination in Pts w/ hematological diseases [May 21, 2022] Rotterdam et al. Annals of Hematology https://t.co/lSI3zQWfnn #COVID19Vaccine #COVID19nCancer #IDonc #COVID19 #mmsm #leusm #lymsm #mpnsm https://t.co/lSI3zQWfnn - view on twitter
e19513 Background: Patients (Pts) with hematologic malignancies (HM) are at greater risk of severe morbidity and mortality caused by COVID19 and show a lower...
Characteristics of Pts w/ hematologic malignancies w/o seroconversion post-#COVID19 3rd vaccine dosing (3V): Real-world data from large midwestern healthcare system [Jun 2, 2022] Hallmeyer et al. @JimW9200 Abstract e19513 #ASCO22 https://t.co/22Q2IGyoS6 #COVID19Vaccine #IDonc https://t.co/22Q2IGyoS6 - view on twitter
Original Article from The New England Journal of Medicine — Early Outpatient Treatment for Covid-19 with Convalescent...
Early Outpatient Treatment for Covid-19 with Convalescent Plasma [Mar 30, 2022] @jhDavidSullivan et al. @NEJM https://t.co/Cqht9Cis3c #NCT04373460 #COVID19CP #COVID19 https://t.co/Cqht9Cis3c - view on twitter
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and...
Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc https://t.co/g3GP7EsUeS - view on twitter